AU2008313459B2 - Diagnostic, predictive and prognostic testing for cancer - Google Patents

Diagnostic, predictive and prognostic testing for cancer Download PDF

Info

Publication number
AU2008313459B2
AU2008313459B2 AU2008313459A AU2008313459A AU2008313459B2 AU 2008313459 B2 AU2008313459 B2 AU 2008313459B2 AU 2008313459 A AU2008313459 A AU 2008313459A AU 2008313459 A AU2008313459 A AU 2008313459A AU 2008313459 B2 AU2008313459 B2 AU 2008313459B2
Authority
AU
Australia
Prior art keywords
biomarker
cancer
level
aurora
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008313459A
Other languages
English (en)
Other versions
AU2008313459A1 (en
Inventor
Kai Stoeber
Gareth Hayden Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Cancer Diagnostics Ltd
Original Assignee
Cambridge Cancer Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Cancer Diagnostics Ltd filed Critical Cambridge Cancer Diagnostics Ltd
Publication of AU2008313459A1 publication Critical patent/AU2008313459A1/en
Application granted granted Critical
Publication of AU2008313459B2 publication Critical patent/AU2008313459B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008313459A 2007-10-15 2008-10-15 Diagnostic, predictive and prognostic testing for cancer Ceased AU2008313459B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0720113.0 2007-10-15
GBGB0720113.0A GB0720113D0 (en) 2007-10-15 2007-10-15 Diagnostic, prognostic and predictive testing for cancer
PCT/GB2008/003501 WO2009050461A1 (en) 2007-10-15 2008-10-15 Diagnostic, predictive and prognostic testing for cancer

Publications (2)

Publication Number Publication Date
AU2008313459A1 AU2008313459A1 (en) 2009-04-23
AU2008313459B2 true AU2008313459B2 (en) 2013-01-24

Family

ID=38813827

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008313459A Ceased AU2008313459B2 (en) 2007-10-15 2008-10-15 Diagnostic, predictive and prognostic testing for cancer

Country Status (11)

Country Link
US (3) US8512716B2 (enExample)
EP (1) EP2208070B1 (enExample)
JP (2) JP5559056B2 (enExample)
CN (1) CN101896819A (enExample)
AU (1) AU2008313459B2 (enExample)
CA (1) CA2702653A1 (enExample)
DK (1) DK2208070T3 (enExample)
ES (1) ES2395890T3 (enExample)
GB (1) GB0720113D0 (enExample)
PT (1) PT2208070E (enExample)
WO (1) WO2009050461A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0921873D0 (en) * 2009-12-15 2010-01-27 Cytosystems Ltd Assay
MX382244B (es) * 2010-07-23 2025-03-13 Harvard College Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales
WO2014179959A1 (en) * 2013-05-09 2014-11-13 The Procter & Gamble Company Method and system for assessing health condition
CN103592444A (zh) * 2013-11-27 2014-02-19 中国人民解放军沈阳军区总医院 一种检测乳腺癌中cyclin G1蛋白表达并进行预后评估的方法
US9857354B2 (en) 2014-06-01 2018-01-02 Novazoi Theranostics, Inc. Compositions and methods for prognosis and treatment of neoplasm
WO2016131875A1 (en) * 2015-02-17 2016-08-25 Biontech Diagnostics Gmbh Methods and kits for the molecular subtyping of bladder cancer
ES2911415T3 (es) 2015-06-08 2022-05-19 Arquer Diagnostics Ltd Métodos y kits
WO2016198833A2 (en) 2015-06-08 2016-12-15 Arquer Diagnostics Limited Methods
CN105986034A (zh) * 2016-06-15 2016-10-05 南京卡迪睿伯生物技术有限公司 一组胃癌基因的应用
CN108344868B (zh) * 2018-01-23 2020-05-15 郑州大学第一附属医院 人组蛋白H3 Ser10和Ser28在鉴定人早期胚胎的发育分期中的应用
CN108344867B (zh) * 2018-01-23 2020-05-15 郑州大学第一附属医院 人组蛋白H3 Ser10和Ser28在鉴定人卵母细胞成熟分期中的应用
CN111187833A (zh) * 2018-11-14 2020-05-22 上海生物芯片有限公司 Plk1和bub1b基因联合作为肺癌生物标志物的用途
GB201820867D0 (en) * 2018-12-20 2019-02-06 Arquer Diagnostics Ltd Detection method
CN109988708B (zh) * 2019-02-01 2022-12-09 碳逻辑生物科技(中山)有限公司 一种用于对患有结肠直肠癌的患者进行分型的系统
CN110846413B (zh) * 2019-11-23 2023-05-26 中南大学湘雅三医院 Mafg/mafg-as1/mafg正反馈环作为靶位点检测试剂的应用
CN114019163B (zh) * 2021-11-02 2024-07-23 复旦大学附属中山医院 基于活化b细胞表达的结肠癌预后诊断用标记物及其用途
EP4473477A4 (en) * 2022-02-01 2026-01-14 4D Path Inc IMAGE-BASED DISEASE CHARACTERIZATION SYSTEMS AND METHODS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329177A1 (de) * 1993-08-30 1995-03-02 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Serin-Threonin-Kinasen
DE19915057A1 (de) * 1999-04-01 2000-10-19 Forschungszentrum Borstel Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
EP1422526A1 (en) 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
GB0323225D0 (en) * 2003-10-03 2003-11-05 Ncc Technology Ventures Pte Lt Materials and methods relating to breast cancer classification
US7871769B2 (en) * 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US20050260653A1 (en) * 2004-04-14 2005-11-24 Joshua Labaer Nucleic-acid programmable protein arrays
EP1805676A1 (en) * 2004-09-22 2007-07-11 Tripath Imaging, Inc. Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
KR20070107034A (ko) * 2005-02-18 2007-11-06 아스트라제네카 아베 Ｃｈｋ1 억제제에 대한 반응성의 결정 방법
ATE456053T1 (de) * 2005-12-30 2010-02-15 Ventana Med Syst Inc Na+, k+-atpase-expression bei zervixdysplasie und krebs
WO2007077435A1 (en) * 2005-12-30 2007-07-12 Astex Therapeutics Limited Pharmaceutical compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOING J J ET AL (2002), GUT, vol. 50, no. 3, pages 373-377 *
HETTY A ET AL (2005) BRITISH JOURNAL OF CANCER vol. 93, no. 11, pages 1295-1300 *
SCOTT I S ET AL (2005), NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY vol. 31, no. 5, pages 455-466 *

Also Published As

Publication number Publication date
US20140154680A1 (en) 2014-06-05
GB0720113D0 (en) 2007-11-28
EP2208070A1 (en) 2010-07-21
JP2011501809A (ja) 2011-01-13
DK2208070T3 (da) 2012-12-17
WO2009050461A1 (en) 2009-04-23
JP2014095726A (ja) 2014-05-22
US20100285474A1 (en) 2010-11-11
US20180223366A1 (en) 2018-08-09
CN101896819A (zh) 2010-11-24
AU2008313459A1 (en) 2009-04-23
EP2208070B1 (en) 2012-10-03
US8512716B2 (en) 2013-08-20
JP5837630B2 (ja) 2015-12-24
JP5559056B2 (ja) 2014-07-23
CA2702653A1 (en) 2009-04-23
PT2208070E (pt) 2013-01-08
ES2395890T3 (es) 2013-02-15

Similar Documents

Publication Publication Date Title
US8512716B2 (en) Diagnostic, predictive and prognostic testing for cancer
Heckl et al. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium
Su et al. Paired box-1 (PAX1) activates multiple phosphatases and inhibits kinase cascades in cervical cancer
Guo et al. Decreased expression of SOX6 confers a poor prognosis in hepatocellular carcinoma
Ho et al. Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma
Li et al. Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma
US20120245051A1 (en) Objective, quantitative method to predict histological subtype in non-small cell lung cancer
Pierssens et al. Chromosome instability in tumor resection margins of primary OSCC is a predictor of local recurrence
Wu et al. Combining the tyrosine kinase inhibitor cabozantinib and the mTORC1/2 inhibitor sapanisertib blocks ERK pathway activity and suppresses tumor growth in renal cell carcinoma
Moreira et al. Molecular characterization by immunocytochemistry of lung adenocarcinoma on cytology specimens
JP4848355B2 (ja) 臨床診療における新規増殖マーカーおよび癌の予後または診断のためのそれらの用途
Nolasco-Quiroga et al. Increased expression of FAK isoforms as potential cancer biomarkers in ovarian cancer
EP2742358A1 (en) Methods for diagnosing cancer
Bai et al. DUSP7 inhibits cervical cancer progression by inactivating the RAS pathway
KR20240156639A (ko) 암 진단 및 prmt5 억제제에 의한 치료
Harb et al. PYCR1, BANF1, and STARD8 expression in gastric carcinoma: a clinicopathologic, prognostic, and immunohistochemical study
Mamat@ Yusof et al. Gene expression and soluble protein level of PD-1 and its ligands (PD-L1 and PD-L2) in endometrial cancer
US8071815B2 (en) CTIP2 expression in squamous cell carcinoma
GB2519830A (en) Methods for monitoring treatment response and relapse in ovarian cancer
Davidson et al. Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma
Liu et al. Expression of p53, p16 and cyclooxygenase‐2 in esophageal cancer with tissue microarray
CN102099493A (zh) 用于预测对抗癌疗法的反应性的组合方法
JP2009524048A (ja) Ｓｈｃタンパク質を使用して消化管および他の癌の再発の予後を診断するための方法
US20110217296A1 (en) Method for selecting patients for treatment with an egfr inhibitor
WO2016133860A1 (en) Cancer biomarkers and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired